Efficacy of immunosuppressive therapy for children with aplastic anemia

WANG Ying-Chao; YIN Chu-Yun; FENG Lei; WANG Chun-Mei; MA Li-Na; WEI Yong-Wei; SHENG Guang-Yao

PDF(937 KB)

Chinese Journal of Contemporary Pediatrics ›› 2012, Vol. 14 ›› Issue (1) : 33-37.

CLINICAL RESEARCH

Efficacy of immunosuppressive therapy for children with aplastic anemia

WANG Ying-Chao, YIN Chu-Yun, FENG Lei, WANG Chun-Mei, MA Li-Na, WEI Yong-Wei, SHENG Guang-Yao

Author information +

History +

Abstract

OBJECTIVE: To study the effectiveness and safety of immunosuppressive therapy (IST) in the treatment of childhood aplastic anemia (AA) and to study the main factors influencing the effectiveness. METHODS: The clinical data of 55 children with severe aplastic anemia (SAA) and 51 children with chronic aplastic anemia (CAA) were retrospectively analyzed. All patients received IST from January 2007 to December 2010. RESULTS: In children with CAA, the effective rate of antithymocyte globulin (ATG) plus cyclosporine A(CsA) combination therapy was significantly higher than that of CsA alone (80% vs 44%; P<0.05); in children with SAA, the effective rate of ATG plus CsA combination therapy was also significantly higher than that of CsA alone (75% vs 40%; P<0.05). No patients developed clonal disease such as myelodysplastic syndrome, paroxysmal nocturn hemoglobinuria or acute myelocytic leukemia. In patients treated with the ATG plus CsA combination therapy, the response rate was relatively high for children whose disease course was less than six months, bone marrow hematopoietic area was more than 40%, had no severe infections, and experienced granulocyte colony stimulating factor (G-CSF) reaction during the early treatment; however, it was not related to AA subtypes and age. CONCLUSIONS: ATG plus CsA combination therapy is effective and safe in the treatment of childhood AA. The disease course, bone marrow hematopoietic area, severe infections and G-CSF reaction to early treatment are the main factors influencing the therapeutic effects.

Key words

Aplastic anemia / Antithymocyte globulin / Cyclosporine A / Child

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

WANG Ying-Chao, YIN Chu-Yun, FENG Lei, WANG Chun-Mei, MA Li-Na, WEI Yong-Wei, SHENG Guang-Yao. Efficacy of immunosuppressive therapy for children with aplastic anemia[J]. Chinese Journal of Contemporary Pediatrics. 2012, 14(1): 33-37

References

［1］Brodsky RA, Jones RJ. Aplastic aneamia［J］. Lancet, 2005, 365(9471): 1647-1656.

［2］中华医学会儿科学分会血液学组，中华儿科杂志编辑委员会.小儿再生障碍性贫血的诊疗建议［J］.中华儿科杂志, 2001,39(7): 422-423.

［3］黄绍良，黄永兰. 儿童特发性再生障碍性贫血的诊断与治疗［J］.中国当代儿科杂志，2009，11(2)：81-87.

［4］Frickhofen N, Heimpel H, Kahwasser JP, Schrezenmeier H. Antithymocyte globulin with or without cyelosporin A: 11-year follow-up of a randomized trial comparing treatments of aplastic anemia［J］. Blood, 2003, 101(4): 1236-1242.

［5］Yamazaki H, Sugimori C, Chuhjo T, Nakao S. Cyclosporine therapy for acquired aplastic anemia: predictive factors for the response and long term prognosis［J］. Int J Hematol, 2007, 85(3): 186-190.

［6］于芳,唐锁勤,王建文.抗胸腺球蛋白/抗淋巴细胞球蛋白治疗重型再生障碍性贫血的疗效及其并发症［J］.中国当代儿科杂志，2006，8(6):479-481.

［7］Scheinberg P, Wu CO, Nunez O, Boss C, Sloand EM, Young NS. Treatment of severe aplastic anemia with a combination of horse antithymcyte globulin and cyclosporine, with or without sirolimus: a prospective randomized study［J］. Haematologica, 2009, 94(3): 348-354.

［8］谢垒，盛光耀，徐学聚，王颖超，赵晓明. 抗胸腺细胞球蛋白联合环孢素治疗重型再生障碍性贫血［J］. 实用儿科临床杂志，2011，26(9)：701-702.

［9］Scheinberg P, Wu CO, Nunez O, Young NS. Long-term outcome of pediatric patients with severe aplastic anemia treated with antithymocyte globulin and cyclosporine［J］. J Pediatr, 2008, 153(6): 814-819.

［10］Passweg JR, Tichelli A. Immunosuppressive treatment for aplastic anemia: are we hitting the ceiling［J］. Haematologica, 2009, 94(3): 310-312.

［11］Howard SC, Naidu PE, Hu XJ, Jeng MR, Rodriguez-Galindo C, Rieman MD, et al. Natural history of moderateaplastic anemia in children［J］. Pediatr Blood Cancer, 2004, 43 (5): 545-551.

［12］Marsh J, Schrezenmeier H, Matin P, Ilhan O, Ljungman P, McCann S, et al. Prospective randomized multicenter study comparing cyclosporine alone versus the combination of antithymocyte globulin and cyclosporine for treatment of patient with nosevere aplastic anemia: a report from the European Blood and Marrow Transplant (EBMT) Severe Aplastic Anemia Working Party［J］. Blood, 1999, 93(7): 2191-2195.

［13］Perez-Albuerne ED, Eapen M, Klein J, Gross TJ, Lipton JM, Baker KS, et al. Outcome of unrelated donor stem cell transplantation for children with severe aplastic anemia［J］. Br J Haematol, 2008, 141(2): 216-223.

［14］Young NS, Calado RT, Scheinberg P. Current concepts in the pathophysiology and treatment of aplastic anemia［J］. Blood, 2006, 108(8): 2509-2519.

［15］Dufour C, Ferretti E, Bagnasco F, Burlando O, Lanciotti M, Ramenghi U, et al. Changes in cytokine profile pre-and post-immunosuppression in acquired aplastic anemia［J］. Heamatologica, 2009, 94 (12): 1743-1747.

［16］Scheinberg P, Nunez O, Young NS. Retreatment with rabbit antithymocyte globulin and ciclosporin for patients with relapsed or refractory severe aplastic anemia［J］. Br J Haematol, 2006, 133 (6): 622-627.

［17］Davies JK, Guinan EC. An update on the management of severe idiopathic aplastic aneamia in children［J］. Br J Heamotol, 2007, 136(4): 549-564.

［18］Tichelli A, Schrezenmeier H, Socié G,Marsh J, Bacigalupo A, Dührsen U, et al. A randomized controlled study in patients with newly diagnosed severe aplastic anemia receiving antithymocyte globulin (ATG), cyclosporine, with or without G-CSF: a study of the SAA Working Party of the European Group for Blood and Marrow Transplantation［J］. Blood, 2011, 117(17): 4434-4441.

［19］Socie G, Mary JY, Sehrezenmerir H, Marsh J, Bacigalupo A, Locasciulli A, et al. Granulocyte-stimulating factor and severe aplastic anemia: a survey by the European Group for Blood and Marrow Transplantation (EBMT)［J］. Blood, 2007, 109(7): 2794-2796.

［20］Bacigalupo A, Brand R, Oneto R, Bruno B, Socié G, Passweg J, et a1. Treatment of acquired severe aplastic anemia: bone marrow transplantation compared with immunos uppressive therapy--The European Group for Blood and Marrow Transplantation experience［J］. Semin Hematol, 2000, 37(1): 69-80.

［21］张丽红，王慧君，张莉，周康，杨栋林，阎嶂松，等．再生障碍性贫血骨髓造血细胞遗传不稳定性的意义［J］.中华血液学杂志，2010，31(4)：219-222.